Literature DB >> 4031948

Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 3. The effect of thymectomy.

H J Oosterhuis, P C Limburg, E Hummel-Tappel, W Van den Burg, T H The.   

Abstract

The clinical condition and the serum levels of antibodies to acetylcholine receptor protein were followed in 30 patients with myasthenia gravis before and in a period varying from 2 to 4 (mean 3) yr after thymectomy. Twenty-five patients improved in the 2 yr following thymectomy. A highly significant correlation was found between the change in clinical condition and the change in antibody levels. Only 3 patients improved without a fall of antibody level. Prethymectomy antibody levels were positively correlated with the severity of the clinical condition and with the degree of thymus hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031948     DOI: 10.1016/0022-510x(85)90144-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

Review 1.  Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review.

Authors:  Frédérique Truffault; Vincent de Montpreville; Bruno Eymard; Tarek Sharshar; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 2.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 3.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

4.  Temporal deterioration of neurological symptoms and increase of serum acetylcholine receptor antibody levels after thymectomy: a case report of a cat with myasthenia gravis.

Authors:  Nao Nagata; Takuma Miyoshi; Yuzo Otake; Hitomi Suzuki; Yumiko Kagawa; Tetsushi Yamagami; Mitsuhiro Irie
Journal:  J Vet Med Sci       Date:  2016-09-03       Impact factor: 1.267

5.  Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial.

Authors:  Siegfried Kohler; Stefanie Märschenz; Ulrike Grittner; Tobias Alexander; Falk Hiepe; Andreas Meisel
Journal:  BMJ Open       Date:  2019-01-28       Impact factor: 2.692

6.  The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis.

Authors:  Florit Marcuse; Lloyd Brandts; Daan Moens; Jan Damoiseaux; Monique Hochstenbag; Janneke G J Hoeijmakers; Jos G Maessen; Marc De Baets
Journal:  Eur J Neurol       Date:  2022-01-09       Impact factor: 6.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.